

Ref No.: ZLL/CS/BM/BSE-NSE

Date: 11.02.2026

BSE Limited, Compliance Department, P. J. Towers, Dalal Street, Mumbai – 400 001 (Scrip Code - 541400)	National Stock Exchange of India Limited, Listing Compliance Department, Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
--	---

Dear Sir,

Sub : Outcome of Board Meeting held on 11.02.2026

Ref : Notice of Board Meeting dt. 05.02.2026

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today, 11th February, 2026 have inter-alia, considered and approved the following:

1. The Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and nine months ended 31st December, 2025.

Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Deloitte Haskins & Sells LLP, Statutory Auditors of the Company is enclosed herewith.

2. Investment of upto USD 15,000 for incorporating a wholly owned subsidiary in Chile, LATAM region.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CI R/2023/123 dated July 13, 2023 are enclosed as **Annexure I**.

The Board Meeting commenced at 04.00 p.m. (IST) and concluded at 06.45 p.m. (IST)

Kindly take the intimation on record.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl : As above

ZIM LABORATORIES LIMITED

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED
FINANCIAL RESULTS****TO THE BOARD OF DIRECTORS OF
ZIM LABORATORIES LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **ZIM LABORATORIES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entities:

Name of the Company	Relationship
ZIM Laboratories Limited, India	Parent Company
ZIM Laboratories FZE, Sharjah	Subsidiary Company
ZIM Health Technologies Limited, India	Subsidiary Company
SIA ZIM Laboratories Limited, Latvia	Subsidiary Company
ZIM Thinorals Private Limited, India	Subsidiary Company
ZIMTAS PTY Limited, Australia	Subsidiary Company
ZIM Laboratories Middle East DMCC, Dubai	Step-Down Subsidiary
ZIM Scientific Office LLC, Dubai	Step-Down Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Deloitte
Haskins & Sells LLP**

6. The consolidated financial results of the Company for the quarter and nine months ended December 31, 2024 and year ended March 31, 2025 included in the Statement, were reviewed/ audited by another auditor who expressed an unmodified conclusion/ opinion on those statements on February 10, 2025 for the quarter and nine months ended December 31, 2025 and May 20, 2025 for the year ended March 31, 2025.

Our conclusion on the statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Viral
Rajnikant
Shah



Digitally signed by
Viral Rajnikant Shah
Date: 2026.02.11
17:18:35 +05'30'

Viral R. Shah
Partner
(Membership No. 117654)
(UDIN: 26117654IRRCNF7817)

Place: Mumbai
Date: February 11, 2026

RB



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		As at 31 December 2025 (Unaudited)	As at 30 September 2025 (Unaudited)	As at 31 December 2024 (Unaudited) Refer Note 3	As at 31 December 2025 (Unaudited)	As at 31 December 2024 (Unaudited) Refer Note 3	As at 31 March 2025 (Audited) Refer Note 3
1	Income						
	a) Revenue from operations	10,865.93	8,871.13	9,633.03	26,912.67	27,029.80	37,903.10
	b) Other income	170.15	204.30	175.46	522.08	407.43	578.41
	Total income	11,036.08	9,075.43	9,808.49	27,434.75	27,437.23	38,481.51
2	Expenses						
	a) Cost of materials consumed	4,322.76	4,349.90	3,987.54	11,434.39	10,640.31	15,500.40
	b) Purchases of stock-in-trade	58.68	292.89	248.65	510.87	828.23	1,157.82
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	478.21	(678.38)	(110.78)	(120.31)	490.79	126.65
	d) Employee benefits	1,557.97	1,631.99	1,447.47	4,651.23	4,443.52	6,075.98
	e) Finance costs	342.91	315.94	273.30	989.20	847.90	1,138.82
	f) Depreciation and amortisation	503.13	498.03	488.07	1,487.51	1,482.44	2,011.34
	g) Other expenses	3,167.74	2,699.44	2,903.87	8,154.76	7,713.94	10,669.56
	Total expenses	10,431.40	9,109.81	9,238.12	27,107.65	26,447.13	36,680.57
3	Profit/(loss) before tax (1-2)	604.68	(34.38)	570.37	327.10	990.10	1,800.94
4	Tax expense/(credit)						
	Current Tax	149.79	2.10	74.76	160.61	127.08	467.41
	Deferred Tax	15.13	5.98	95.53	(43.32)	134.97	117.03
	Total tax expense	164.92	8.08	170.29	117.29	262.05	584.44
5	Profit/(loss) after tax (3-4)	439.76	(42.46)	400.08	209.81	728.05	1,216.50
6	Other comprehensive income - profit/(loss)						
	a) Items that will not be reclassified to profit or loss	(18.99)	(18.99)	(13.47)	(56.97)	(40.41)	(75.95)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	5.53	5.53	3.92	16.59	11.76	22.11
	c) Items that may be reclassified to profit or loss	100.13	45.94	37.80	201.42	65.14	51.09
	d) Tax (expense)/credit on the items that will be reclassified to profit or loss	-	-	-	-	-	-
	Other comprehensive income (net of tax) - profit/(loss)	86.67	32.48	28.25	161.04	36.49	(2.75)
7	Total comprehensive income (5+6)	526.43	(9.98)	428.33	370.85	764.54	1,213.75
8	Net Profit after tax attributable to						
	Owners	439.77	(42.46)	400.08	209.82	728.05	1,216.52
	Non-controlling interest	(0.01)	-	-	(0.01)	-	(0.02)
9	Other comprehensive Income attributable to						
	Owners	86.67	32.48	28.25	161.04	36.50	(2.75)
	Non-controlling interest	-	-	-	-	(0.01)	-
10	Total Comprehensive Income attributable to						
	Owners	526.44	(9.98)	428.33	370.86	764.55	1,213.77
	Non-controlling interest	(0.01)	-	-	(0.01)	(0.01)	(0.02)
11	Paid-up equity share capital (face value of Rs. 10/- each)	4,873.58	4,873.58	4,872.58	4,873.58	4,872.58	4,872.58
12	Other equity (revaluation reserve : Rs. Nil)						20,351.17
13	Earnings per share (face value of Rs. 10/- each) (not annualised for the quarters) (Rs.)						
	Basic	0.90	(0.09)	0.82	0.43	1.49	2.50
	Diluted	0.90	(0.09)	0.82	0.43	1.49	2.50

RB

Notes :

1) The above unaudited consolidated financial results of ZIM Laboratories Limited ('the Parent' or 'the Company') and its subsidiaries (together referred to as 'Group') were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11 February 2026. The above results have been subjected to limited review by Statutory Auditor of the Parent.

2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).

3) The consolidated financial results of the Group for the quarter & nine months ended 31 December 2024 and year ended 31 March 2025 were reviewed/audited by another auditor, who expressed an unmodified conclusion/opinion on those results on 10 February 2025 and 20 May 2025 respectively.

4) The Group is principally engaged in a single business segment which is "pharmaceuticals". There is no separate reportable segment as per Ind AS 108 - Operating Segments.

Place: Nagpur
Date: 11 February 2026

Anwar
Siraj Daud

Anwar S. Daud
Managing Director

Digitally signed by Anwar Sraij Daud
DN: c=IN, o=Personal, postalCode=440002, st=Nagpur, st=Maharashtra, street=opposite harsuriya high school
Shanti nagpur, Nagpur City HQ, Maharashtra India 44002
date=2026.02.11 17:02:20+0530

RB

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ZIM LABORATORIES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **ZIM LABORATORIES LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The standalone financial results of the Company for the quarter and nine months ended December 31, 2025 and year ended March 31, 2025 included in the Statement, were reviewed/ audited by another auditor who expressed an unmodified conclusion/ opinion on those statements on February 10, 2025 for the quarter and nine months ended December 31, 2025 and May 20, 2025 for the year ended March 31, 2025.

Our conclusion on the statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Viral

Rajnikant
Shah

Digitally signed by
Viral Rajnikant Shah
Date: 2026.02.11
17:17:08 +05'30'

Viral R. Shah

Partner

(Membership No. 117654)

(UDIN: 26117654NSXYP09076)

Place: Mumbai

Date: February 11, 2026



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		(Unaudited)	(Unaudited)	(Unaudited) Refer Note 3	(Unaudited)	(Unaudited) Refer Note 3	(Audited) Refer Note 3
1	Income						
	a) Revenue from operations	10,780.58	8,839.43	9,539.50	26,762.78	26,712.04	37,563.55
	b) Other income	171.18	204.39	176.47	523.13	406.65	562.09
	Total income	10,951.76	9,043.82	9,715.97	27,285.91	27,118.69	38,125.64
2	Expenses						
	a) Cost of materials consumed	4,322.76	4,349.90	3,987.54	11,434.39	10,640.31	15,500.40
	b) Purchases of stock-in-trade	58.68	292.89	248.65	510.87	828.23	1,157.82
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	496.51	(678.38)	(110.78)	(102.01)	490.79	126.65
	d) Employee benefits expenses	1,478.54	1,546.06	1,315.90	4,382.02	4,107.71	5,640.62
	e) Finance costs	342.91	315.94	273.30	989.20	847.66	1,138.58
	f) Depreciation and amortisation	484.86	482.83	476.83	1,446.67	1,465.77	1,989.14
	g) Other expenses	3,174.54	2,711.77	2,921.75	8,237.29	7,841.86	10,811.22
	Total expenses	10,358.80	9,021.01	9,113.19	26,898.43	26,222.33	36,364.43
3	Profit/(loss) before tax (1-2)	592.96	22.81	602.78	387.48	896.36	1,761.21
4	Tax expense /(credit)						
	Current Tax	146.71	-	65.87	146.71	110.49	444.69
	Deferred Tax	20.35	11.21	102.06	(27.54)	153.55	142.12
	Total tax expense /(credit)	167.06	11.21	167.93	119.17	264.04	586.81
5	Profit/(loss) after tax (3-4)	425.90	11.60	434.85	268.31	632.32	1,174.40
6	Other comprehensive income - profit/(loss)						
	a) Items that will not be reclassified to profit or loss	(18.99)	(18.99)	(13.47)	(56.97)	(40.41)	(75.95)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	5.53	5.53	3.92	16.59	11.76	22.11
	Other comprehensive income (net of tax) - profit/(loss)	(13.46)	(13.46)	(9.55)	(40.38)	(28.65)	(53.84)
7	Total comprehensive income (5+6)	412.44	(1.86)	425.30	227.93	603.67	1,120.56
8	Paid-up equity share capital (face value of Rs. 10/- each)	4,873.58	4,873.58	4,872.58	4,873.58	4,872.58	4,872.58
9	Other equity (revaluation reserve : Rs. Nil)						19,578.80
10	Earnings per share (face value of Rs. 10/- each) (not annualised) (Rs.)						
	Basic	0.87	0.03	0.89	0.55	1.30	2.41
	Diluted	0.87	0.03	0.89	0.55	1.30	2.41

RB

Notes :

- 1) The above unaudited standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11 February 2026. The above results have been subjected to limited review by Statutory Auditor of the Company.
- 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The standalone financial results of the Company for the quarter & nine months ended 31 December 2024 and year ended 31 March 2025 were reviewed/audited by another auditor, who expressed an unmodified conclusion/opinion on those results on 10 February 2025 and 20 May 2025 respectively.
- 4) The Company is principally engaged in a single business segment which is "pharmaceuticals". There is no separate reportable segment as per Ind AS 108 - Operating Segments.

Place: Nagpur
Date: 11 February 2026

Anwar
Siraj Daud
Anwar S. Daud
Managing Director

Digitally signed by Anwar Siraj Daud
DN: cn=Anwar Siraj Daud, postalCode=440002, o=Nagpur,
ou=Maharashtra, street=oppo to busanaga high school,
Shanti nagar, Nagpur City H.O, Maharashtra India 440002
SerialNumber=46, c=IN
2.5.4.20=51623a503b2aeb1231c0f8d81a7a090a0f0bc
c793b7e6c0a0c0795a03,
serialNumber=46, c=IN, o=Nagpur, ou=Maharashtra, postalCode=440002,
ou=Maharashtra, street=oppo to busanaga high school,
Shanti nagar, Nagpur City H.O, Maharashtra India 440002
email=anwar.daud@anwar.com, cn=Anwar Siraj Daud
Date: 2026.02.11 17:03:11 +05'30'

RB

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July, 2023

Annexure - I

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Entity Name: ZIM Laboratories SpA or any other name as approved by the regulatory authority. Turnover: NIL (As the Company is yet to be incorporated)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	At present, the said transaction is not a related party transaction. However, once is entity is incorporated and investment in the capital of the said entity is completed, the said entity will be termed as related party to the Company and any transaction with the entity would be categorised as related party transaction. Dr. Anwar Daud and Mr. Zulfiquar Kamal, Promoters of the Company would be appointed as Directors on the Board of ZIM Laboratories SpA.
3	Industry to which the entity being acquired belongs	Pharmaceutical
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The incorporation of Wholly owned subsidiary is with an objective of expansion and development of business in the LATAM region.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Any approvals or permission, if required for incorporation of the entity in Chile, LATAM region, would be obtained by the entity.
6	Indicative time period for completion of the acquisition	Not Applicable
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration

ZIM LABORATORIES LIMITED



Zeal & Innovation in Medicine

8	Cost of acquisition and/or the price at which the shares are acquired	ZIM Laboratories Limited would invest upto USD 15,000 or any equivalent amount in the relevant currency in the share capital of the Wholly Owned subsidiary.
9	Percentage of shareholding /control acquired and / or number of shares acquired	After the proposed investment, the incorporated entity would be the Wholly owned subsidiary of the Company.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable as the Company is yet to be Incorporated.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.7118.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960